Nerandomilast is a phosphodiesterase 4 inhibitor used to treat idiopathic pulmonary fibrosis in adults. Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype.
- Mechanism
- Curator reviewed · 7 references
Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor. PDE4 is an enzyme that regulates inflammatory processes. PDE4 has been implicated in the driving the inflammation and fibrosis of the lungs in IPF.
Nerandomilast preferentially inhibits the PDE4B isoenzyme over PDE4A, PDE4C, and PDE4D. PDE4 inactivates cyclic adenosine monophosphate (cAMP) by hydrolyzing it. Nerandomilast elevates intracellular cAMP levels through PDE4B inhibition, which reduces the expression of pro-fibrotic growth factors and inflammatory cytokines overexpressed in IPF, such as mitogen-activated protein kinase (MAPK) and transforming growth factor beta (TGFβ).
- Primary indication
- Nerandomilast is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients.Curator reviewed · 4 structured indications
- Formula / weight
- C20H25ClN6O2S · 448.97 g/mol (avg)
- First approval
- United States, 2025
- Code names
- BI-1015550 · R-BI 1015550
- Brand names
Resolves to
UHYCLWAANUGUMN-SSEXGKCCSA-NSMILESOCC1(CCC1)NC1=NC(=NC2=C1[S@+]([O-])CC2)N1CCC(CC1)C1=NC=C(Cl)C=N1What you can answer from here — as of September 10, 2026
Which drugs share a target with Nerandomilast, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account